Clinical Aspects of Phage Therapy

Międzybrodzki, Ryszard; Borysowski, Jan; Weber‐Dąbrowska, Beata; Fortuna, Wojciech; Letkiewicz, Sławomir; Szufnarowski, Krzysztof; Pawełczyk, Z; Rogóż, Paweł; Kłak, Marlena; Wojtasik, Elżbieta; Górski, Andrzej

doi:10.1016/b978-0-12-394438-2.00003-7

Cited by 313 publications

(328 citation statements)

References 33 publications

Supporting

Mentioning

311

Contrasting

Unclassified

Order By: Relevance

“…It should be emphasized that no clinical or laboratory signs of hepatic injury were noted in normal individuals and patients treated with phages [although some of them had some extent of liver dysfuntion (moderate elevation of aminotransferases)], so clinical phage therapy appears to be free of hepatotoxicity 58, 59, 60. This confirms earlier data from experiments in mice 61 and in broilers in which dietary supplementation with phages increased liver weight 62.…”

Section: Safety Of Phage Therapysupporting

confidence: 77%

Therapeutic potential of phages in autoimmune liver diseases

Górski

Jończyk‐Matysiak

Łusiak-Szelachowska

et al. 2018

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryAutoimmune liver disease (ALD) poses a difficult medical challenge, as there is a significant number of patients in whom current therapy offers questionable or no benefit, yet its side effects may be serious, including the development of malignancy. Bacterial viruses (phages) have been recognized increasingly as immunomodulators contributing to immune homeostasis and curbing inflammation. Accumulating data suggest that phages may be useful in immunotherapy of ALD. Phages have been shown to down‐regulate the expression and/or production and activity of factors associated with hepatic injury [reactive oxygen species, Toll‐like receptor (TLR)‐4 activation, nuclear factor kappa B (NF‐κB) activation, proinflammatory and procoagulant activities of platelets] and up‐regulate the expression and/or production of factors demonstrated as playing a protective role [interleukin (IL)‐10, IL‐1 receptor antagonist].

show abstract

Section: Safety Of Phage Therapysupporting

confidence: 77%

Therapeutic potential of phages in autoimmune liver diseases

Górski

Jończyk‐Matysiak

Łusiak-Szelachowska

et al. 2018

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Adult patients with various infections (genitourinary tract infections, prostatitis, soft tissue infections, bone infection, and upper and lower respiratory tract infections) resistant to antibiotic treatment received phage treatment under the therapeutic protocol entitled ''Experimental phage therapy of drug-resistant bacterial infections, including MRSA infections'' treated at the PTU in Wroc1aw (10).…”

Section: Methodsmentioning

confidence: 99%

“…The intrarectal route of treatment was 10-20 mL twice daily. Phage administration took place for 12 weeks, but this could be extended for up to 12 more weeks in cases when infection remained (10). The S. aureus phage cocktail MS-1 was administered for 6 weeks.…”

Section: Methodsmentioning

confidence: 99%

Phage Neutralization by Sera of Patients Receiving Phage Therapy

et al. 2014

Self Cite

View full text Add to dashboard Cite

The aim of our investigation was to verify whether phage therapy (PT) can induce antiphage antibodies. The antiphage activity was determined in sera from 122 patients from the Phage Therapy Unit in Wroc1aw with bacterial infections before and during PT, and in sera from 30 healthy volunteers using a neutralization test. Furthermore, levels of antiphage antibodies were investigated in sera of 19 patients receiving staphylococcal phages and sera of 20 healthy volunteers using enzyme-linked immunosorbent assay. The phages were administered orally, locally, orally/locally, intrarectally, or orally/intrarectally. The rate of phage inactivation (K) estimated the level of phages' neutralization by human sera. Low K rates were found in sera of healthy volunteers (K £ 1.73). Low K rates were detected before PT (K £ 1.64). High antiphage activity of sera K > 18 was observed in 12.3% of examined patients (n = 15) treated with phages locally (n = 13) or locally/orally (n = 2) from 15 to 60 days of PT. High K rates were found in patients treated with some Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecalis phages. Low K rates were observed during PT in sera of patients using phages orally (K £ 1.04). Increased inactivation of phages by sera of patients receiving PT decreased after therapy. These results suggest that the antiphage activity in patients' sera depends on the route of phage administration and phage type. The induction of antiphage activity of sera during or after PT does not exclude a favorable result of PT.

show abstract

“…D'un côté, une stratégie de traitement « prêt-à-porter » pour la prise en charge des infections avec pronos- 5 Collection de pus dans l'espace pleural (entre les poumons et la surface interne de la paroi thoracique). [19,[29][30][31][32], l'administration de phages peut, dans certains cas, s'accompagner de la production d'anticorps dont certains sont neutralisants (provoquant l'inactivation de la particule virale) [33,34]. Les conséquences cliniques liées à la présence de ces anticorps ne semblent cependant pas influencer le pronostic infectieux et l'efficacité du traitement [35].…”

Section: Prêt-à-porter Et Sur Mesureunclassified

La phagothérapie

Dufour

Debarbieux

2017

Med Sci (Paris)

View full text Add to dashboard Cite

Clinical Aspects of Phage Therapy

Cited by 313 publications

References 33 publications

Therapeutic potential of phages in autoimmune liver diseases

Therapeutic potential of phages in autoimmune liver diseases

Phage Neutralization by Sera of Patients Receiving Phage Therapy

La phagothérapie

Contact Info

Product

Resources

About